Pharma Mar (OTCMKTS:PHMMF) Sees Large Drop in Short Interest

by · The Cerbat Gem

Pharma Mar (OTCMKTS:PHMMF – Get Free Report) saw a significant decline in short interest in June. As of June 30th, there was short interest totaling 252 shares, a decline of 99.3% from the June 15th total of 34,651 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days.

Pharma Mar Stock Down 3.6%

Shares of OTCMKTS:PHMMF traded down $3.44 during midday trading on Friday, reaching $90.90. The company had a trading volume of 102 shares, compared to its average volume of 27. The company’s 50 day moving average price is $95.96 and its 200 day moving average price is $93.87. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.02 and a quick ratio of 2.44. Pharma Mar has a 52-week low of $77.41 and a 52-week high of $110.40.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on PHMMF shares. BTIG Research started coverage on Pharma Mar in a report on Thursday, April 23rd. They set a “buy” rating for the company. Zacks Research raised shares of Pharma Mar to a “hold” rating in a research report on Monday, June 15th. Finally, Chardan Capital raised shares of Pharma Mar to a “strong-buy” rating in a research report on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy”.

Check Out Our Latest Research Report on PHMMF

Pharma Mar Company Profile

(Get Free Report)

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.

Featured Stories